Figure 4

Changes in Iba1 protein expression following central anti-TNF treatment after SCI. (A) Quantification of Iba1 protein expression in spinal cord tissue of saline-, XPro1595-, and etanercept-treated mice at 7 and 28 days after SCI. Data are normalized to β-actin protein expression. Representative experiments are shown. Results, expressed as percent of control, are the mean ± SEM of three animals per group. #P <0.05 versus XPro1595 and etanercept; *P <0.05, **P <0.01, and ***P <0.001 versus control by one-way ANOVA with Tukey’s test. (B) Representative low magnification photomicrographs of thoracic spinal cord sections from saline-, XPro1595-, and etanercept-treated mice allowed 7 and 35 days survival after SCI and representative high magnification photomicrographs from saline-treated mice allowed 7 and 35 days survival and stained for anti-Iba1. Estimation of the total number of Iba1⁺ cells 7 days after SCI (upper graph) and densitometric analysis of Iba1⁺ cells 35 days after SCI (lower graph) displayed no difference in microglial/macrophage numbers between the different treatment groups. Scale bars: low magnification: 100 μm and high magnification: 10 μm.